Skip to content

King Pharmaceuticals KG European Hospital Liability — Year 9

Other product segments

General Liability
3.8%
Commercial Auto Liability
1.6%
International
-0.7%
All other lines
-0.4%

Similar metrics at other companies

CNA Financial logo
CNAMedical Professional Liability — Year 9
1.8%+0.7pp
Greenlight Capital RE, Ltd. logo
GLREHealth — Year 9
0%
Axis Capital Holders logo
AXSInsurance — Year 9
6.5%
Horace Mann Educators logo
HMNAutomobile Liability — Year Nine
0.1%0.0pp
American International Group logo
AIGUK/Europe Casualty and Financial lines — Year 9 (as a percent)
3.3%+0.1pp
CNA Financial logo
CNAOther Professional Liability and Management Liability — Year 9
3.5%+1.0pp

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearNine.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's european hospital liability — year 9.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's european hospital liability — year 9?
King Pharmaceuticals (KG) reported european hospital liability — year 9 of 4.9% in Q4 2025.
What does european hospital liability — year 9 mean?
This metric reports the financial results of the European hospital liability insurance line during the ninth year of the reporting cycle. It serves as a benchmark for the company's success in navigating the regulatory and claims environment specific to European healthcare providers. Investors utilize this metric to gauge the maturity and ongoing contribution of this specific insurance segment to the overall corporate portfolio.